Univerger Tablet (Beraprost Sodium)

Adult dose

Improvement of ulcers, pain, and coldness associated with chronic arterial occlusive disease (Buerger's disease, arteriosclerosis obliterans, diabetic peripheral vascular disease, etc.): The usual adult dose is 0.12mg (6 tablets) of beraprost sodium per day, divided into 3 doses (2 tablets per dose), administered orally after meals. Primary pulmonary hypertension: 1) The usual adult initial dose is 0.06mg (3 tablets) of beraprost sodium per day, divided into 3 doses (1 tablet per dose), administered orally after meals. The dose is then gradually increased while carefully observing symptoms (adverse reactions). If the dose is increased, administer 3-4 times daily, up to a maximum dose of 0.18mg (9 tablets) per day. 2) As patients vary in their tolerance to the medicine, start this product at a low dose and carefully monitor the patient's condition when increasing the dose. 3) Because this product is an oral formulation, it may be ineffective in patients with severe symptoms. If hemodynamic parameters and/or clinical symptoms do not improve sufficiently, appropriate treatment should be provided, such as switching to an injectable formulation or other therapy.

This medication should not be administered to patients with bleeding or coagulopathy issues. Pregnant women or those who may become pregnant should not take this medication. This medication contains lactose, making it unsuitable for patients with lactose intolerance or related genetic disorders. Patients taking anticoagulants, platelet aggregation inhibitors, or thrombolytics should use this medication with caution. Patients who are menstruating or have a tendency to bleed should also use this medication carefully. Patients with severely impaired kidney function may need careful monitoring due to potential increased concentration of the drug in the body. This medication can rarely cause serious side effects such as severe bleeding, shock, interstitial pneumonia, liver dysfunction, angina, and myocardial infarction; therefore, if any unusual symptoms occur, use should be discontinued immediately. Various side effects such as headache, rash, digestive disorders, blood abnormalities, and low blood pressure may occur, so symptoms should be closely monitored. There is a risk of altered consciousness, so special caution is required when driving or operating hazardous machinery. Interactions may occur when used with other anticoagulants or antihypertensive drugs, so consultation with healthcare professionals is advised. Safety has not been established for pregnant women, so administration should be avoided, and nursing mothers are also advised to refrain from potential use. Safety in children has not been established, so caution is necessary when administered to children. Elderly patients may have reduced bodily function, so dosage adjustment may be necessary. This medication should be kept out of the reach of children and should not be transferred to another container. When treating chronic arterial occlusive disease, the potential for adverse reactions should be considered based on dosage.

• Cerebral hemorrhage
• gastrointestinal bleeding
• fundus bleeding
• pulmonary hemorrhage
• shock
• syncope
• loss of consciousness
• interstitial pneumonia
• liver function impairment
• jaundice

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 to 30 degrees Celsius to safely preserve the drug's effectiveness.

Appearance

White to pale yellow film-coated tablets

Package unit

30 tablets/bottle, 200 tablets/bottle